Drug-induced uveitis

Bibliography

• Foster CS, Vitale AT, Jakobiec FA. Diagnosis and treatment of uveitis. 2 edition. Jaypee Brothers Medical Publishers; New Delhi; London: 2013
   Google Scholar
• Moorthy RS, London NJS, Garg SJ, Cunningham ET. Drug-induced uveitis. Curr Opin Ophthalmol 2013;24(6):589-97
   PubMed Web of Science ®Google Scholar
• Akingbehin T, Villada JR. Metipranolol-associated granulomatous anterior uveitis. Br J Ophthalmol 1991;75(9):519-23
   PubMed Web of Science ®Google Scholar
• Georgopoulos M, Polak K, Prager F, et al. Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br J Ophthalmol 2009;93(4):457-62
   PubMed Web of Science ®Google Scholar
• Akler ME, Johnson DW, Burman WJ, Johnson SC. Anterior uveitis and hypotony after intravenous cidofovir for the treatment of cytomegalovirus retinitis. Ophthalmology 1998;105(4):651-7
   PubMed Web of Science ®Google Scholar
• Hinkle CM, Dacey MS, Mandelcorn E, et al. Bilateral uveitis associated with fluoroquinolone therapy. Cutan Ocul Toxicol 2012;31(2):111-16
   PubMed Web of Science ®Google Scholar
• Fraunfelder FW, Suhler EB, Fraunfelder FT. Hepatitis B vaccine and uveitis: an emerging hypothesis suggested by review of 32 case reports. Cutan Ocul Toxicol 2010;29(1):26-9
   PubMed Web of Science ®Google Scholar
• Sham CW, Levinson RD. Uveitis exacerbation after varicella-zoster vaccination in an adult. Arch Ophthalmol 2012;130(6):793-4
   PubMed Web of Science ®Google Scholar
• Ostheimer TA, Burkholder BM, Leung TG, et al. Tattoo-Associated Uveitis. Am J Ophthalmol 2014;158(3):637-43
   PubMed Web of Science ®Google Scholar
• Fraunfelder FW, Rosenbaum JT. Drug-induced uveitis. Incidence, prevention and treatment. Drug Saf Int J Med Toxicol Drug Exp 1997;17(3):197-207
   PubMed Web of Science ®Google Scholar
• Macarol V, Fraunfelder FT. Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol 1994;118(2):220-4
   PubMed Web of Science ®Google Scholar
• Fraunfelder FW, Fraunfelder FT, Jensvold B. Scleritis and other ocular side effects associated with pamidronate disodium. Am J Ophthalmol 2003;135(2):2019-22
   Google Scholar
• Fraunfelder FW, Fraunfelder FT. Adverse ocular drug reactions recently identified by the National Registry of Drug-Induced Ocular Side Effects. Ophthalmology 2004;111(7):1275-9
   PubMed Web of Science ®Google Scholar
• Drug and therapeutics committees: a practical guide. Holloway K, Green T. WHO. WHO Department of Essential Drugs and Medicines Policy, Geneva, Switzerland; 2003. Available from: http://apps.who.int/medicinedocs/pdf/s4882e/s4882e.pdf
   Google Scholar
• Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30(2):239-45
   PubMed Web of Science ®Google Scholar
• London NJ, Garg SJ, Moorthy RS, Cunningham ET. Drug-induced uveitis. J Ophthalmic Inflamm Infect 2013;3(1):43
   Google Scholar
• Moorthy RS, Valluri S, Jampol LM. Drug-induced uveitis. Surv Ophthalmol 1998;42(6):557-70
   PubMed Web of Science ®Google Scholar
• Foster CS, Lass JH, Moran-Wallace K, Giovanoni R. Ocular toxicity of topical antifungal agents. Arch Ophthalmol 1981;99(6):1081-4
   PubMed Web of Science ®Google Scholar
• D’Amico DJ, Libert J, Kenyon KR, et al. Retinal toxicity of intravitreal gentamicin. An electron microscopic study. Invest Ophthalmol Vis Sci 1984;25(5):564-72
   PubMed Web of Science ®Google Scholar
• Koneru PB, Lien EJ, Koda RT. Oculotoxicities of systemically administered drugs. J Ocul Pharmacol 1986;2(4):385-404
   PubMedGoogle Scholar
• Mader R, Narendran A, Lewtas J, et al. Systemic vasculitis following influenza vaccination–report of 3 cases and literature review. J Rheumatol 1993;20(8):1429-31
   PubMed Web of Science ®Google Scholar
• Worlledge S; Hong Kong Treatment Services-Royal Postgraduate Medical School-British Medical Research Council Co-operative study of rifampicin plus ethambutol in daily and intermittent regimens. The detection of rifampicin-dependent antibodies. Scand J Respir Dis 1973;84(S):60-3
   Google Scholar
• Lish A, Berman DH. Tuberculin-triggered panuveitis in a patient recently treated for active pulmonary tuberculosis. Am J Ophthalmol 1993;116(6):771-3
   PubMed Web of Science ®Google Scholar
• Jacobs DS, Piliero PJ, Kuperwaser MG, et al. Acute uveitis associated with rifabutin use in patients with human immunodeficiency virus infection. Am J Ophthalmol 1994;118(6):716-22
   PubMed Web of Science ®Google Scholar
• Shafran SD, Deschênes J, Miller M, et al. Uveitis and pseudojaundice during a regimen of clarithromycin, rifabutin, and ethambutol. MAC Study Group of the Canadian HIV Trials Network. N Engl J Med 1994;330(6):438-9
   PubMed Web of Science ®Google Scholar
• Siegal FP, Eilbott D, Burger H, et al. Dose-limiting toxicity of rifabutin in AIDS-related complex: syndrome of arthralgia/arthritis. AIDS 1990;4(5):433-41
   PubMed Web of Science ®Google Scholar
• D’Amato RJ, Alexander GM, Schwartzman RJ, et al. Evidence for neuromelanin involvement in MPTP-induced neurotoxicity. Nature 1987;327(6120):324-6
   PubMed Web of Science ®Google Scholar
• Ings RM. The melanin binding of drugs and its implications. Drug Metab Rev 1984;15(5-6):1183-212
   PubMed Web of Science ®Google Scholar
• Salazar-Bookaman MM, Wainer I, Patil PN. Relevance of drug-melanin interactions to ocular pharmacology and toxicology. J Ocul Pharmacol 1994;10(1):217-39
   PubMedGoogle Scholar
• Broekhuyse RM, Kuhlmann ED, Winkens HJ. Experimental autoimmune anterior uveitis (EAAU). III. Induction by immunization with purified uveal and skin melanins. Exp Eye Res 1993;56(5):575-83
   PubMed Web of Science ®Google Scholar
• Martins JC, Wilensky JT, Asseff CF, et al. Corticosteroid-induced uveitis. Am J Ophthalmol 1974;77(4):433-7
   PubMed Web of Science ®Google Scholar
• Maier M, Feucht N, Lanzl I, et al. Retinochoroidopathy after intravitreal anti-VEGF treatment]. Ophthalmol Z Dtsch Ophthalmol Ges 2009;106(8):729-34
   Google Scholar
• Butler NJ, Suhler EB. Levofloxacin-associated panuveitis with chorioretinal lesions. Arch Ophthalmol 2012;130(10):1342-4
   PubMed Web of Science ®Google Scholar
• Patel DV, Horne A, House M, et al. The incidence of acute anterior uveitis after intravenous zoledronate. Ophthalmology 2013;120(4):773-6
   PubMed Web of Science ®Google Scholar
• Durnian JM, Olujohungbe A, Kyle G. Bilateral acute uveitis and conjunctivitis after zoledronic acid therapy. Eye (Lond) 2005;19(2):221-2
   PubMed Web of Science ®Google Scholar
• Johnson D, Hollands H, Hollands S, Sharma S. Incidence and characteristics of acute intraocular inflammation after intravitreal injection of bevacizumab: a retrospective cohort study. Can J Ophthalmol 2010;45(3):239-42
   PubMed Web of Science ®Google Scholar
• Okada AA, Keino H, Watanabe T, et al. Recurrence of acute anterior inflammation after intravitreal injection of bevacizumab in uveitis. Jpn J Ophthalmol 2009;53(2):182-4
   PubMed Web of Science ®Google Scholar
• Akduman L, Del Priore LV, Kaplan HJ, Powderly WG. Rifabutin induced vitritis in AIDS patients. Ocul Immunol Inflamm 1996;4(4):219-24
   PubMed Web of Science ®Google Scholar
• Saran BR, Maguire AM, Nichols C, et al. Hypopyon uveitis in patients with acquired immunodeficiency syndrome treated for systemic Mycobacterium avium complex infection with rifabutin. Arch Ophthalmol 1994;112(9):1159-65
   PubMed Web of Science ®Google Scholar
• French DD, Margo CE. Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort. Retina 2008;28(6):889-93
   PubMed Web of Science ®Google Scholar
• Technology report no 69. Wells G, Cranney A, Boucher M, et al. Bisphosphonates for the primary and secondary prevention of osteoporotic fractures in postmenopausal women: a meta-analysis. Canadian Agency for Drugs and Technologies in Health, Ottawa; 2006. Available from: http://www.cadth.ca/media/pdf/371_Bisphosphonates_tr_e_NoAppendix.pdf
   Google Scholar
• Etminan M, Forooghian F, Maberley D. Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study. CMAJ 2012;184(8):E431-4
   PubMed Web of Science ®Google Scholar
• Richards JC, Wiffen SJ. Corneal graft rejection precipitated by uveitis secondary to alendronate sodium therapy. Cornea 2006;25(9):1100-1
   PubMed Web of Science ®Google Scholar
• Haverbeke G, Pertile G, Claes C, Zeyen T. Posterior uveitis: an under-recognized adverse effect of pamidronate: 2 case reports. Bull Soc Belge Ophtalmol 2003(290):71-6
   PubMedGoogle Scholar
• Tan YL, Sims J, Chee SP. Bilateral uveitis secondary to bisphosphonate therapy. Ophthalmologica 2009;223(3):215-16
   PubMed Web of Science ®Google Scholar
• Belliveau MJ, Almeida DRP, Urton TE. Acute anterior uveitis following zoledronic acid infusion for osteoporosis. Can J Ophthalmol 2012;47(5):e22-3
   PubMed Web of Science ®Google Scholar
• Sauty A, Pecherstorfer M, Zimmer-Roth I, et al. Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone 1996;18(2):133-9
   PubMed Web of Science ®Google Scholar
• Makkonen N, Salminen A, Rogers MJ, et al. Contrasting effects of alendronate and clodronate on RAW 264 macrophages: the role of a bisphosphonate metabolite. Eur J Pharm Sci 1999;8(2):109-18
   PubMed Web of Science ®Google Scholar
• Fietta P, Manganelli P, Lodigiani L. Clodronate induced uveitis. Ann Rheum Dis 2003;62(4):378
   PubMed Web of Science ®Google Scholar
• Hoover DR, Peng Y, Saah A, et al. Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression. Arch Ophthalmol 1996;114(7):821-7
   PubMed Web of Science ®Google Scholar
• Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338(13):853-60
   PubMed Web of Science ®Google Scholar
• Lalezari JP, Stagg RJ, Kuppermann BD, et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann Intern Med 1997;126(4):257-63
   PubMed Web of Science ®Google Scholar
• Studies of Ocular Complications of AIDS Research Group. The AIDS Clinical Trials Group. The ganciclovir implant plus oral ganciclovir versus parenteral cidofovir for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: The Ganciclovir Cidofovir Cytomegalovirus Retinitis Trial. Am J Ophthalmol 2001;131(4):457-677
   PubMed Web of Science ®Google Scholar
• Bainbridge JW, Raina J, Shah SM, et al. Ocular complications of intravenous cidofovir for cytomegalovirus retinitis in patients with AIDS. Eye (Lond) 1999;13(Pt3a):353-6
   PubMedGoogle Scholar
• Ambati J, Wynne KB, Angerame MC, Robinson MR. Anterior uveitis associated with intravenous cidofovir use in patients with cytomegalovirus retinitis. Br J Ophthalmol 1999;83(10):1153-8
   PubMed Web of Science ®Google Scholar
• Song MK, Azen SP, Buley A, et al. Effect of anti-cytomegalovirus therapy on the incidence of immune recovery uveitis in AIDS patients with healed cytomegalovirus retinitis. Am J Ophthalmol 2003;136(4):696-702
   PubMed Web of Science ®Google Scholar
• Ball P, Mandell L, Niki Y, Tillotson G. Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Saf 1999;21(5):407-21
   PubMed Web of Science ®Google Scholar
• Grijalva CG, Nuorti JP, Griffin MR. Antibiotic prescription rates for acute respiratory tract infections in US ambulatory settings. JAMA 2009;302(7):758-66
   PubMed Web of Science ®Google Scholar
• Bringas Calvo R, Iglesias Cortiñas D. Acute and bilateral uveitis secondary to moxifloxacin. Arch Soc Esp Oftalmol 2004;79(7):357-9
   PubMedGoogle Scholar
• Wefers Bettink-Remeijer M, Brouwers K, van Langenhove L, et al. Uveitis-like syndrome and iris transillumination after the use of oral moxifloxacin. Eye (Lond) 2009;23(12):2260-2
   PubMed Web of Science ®Google Scholar
• Morshedi RG, Bettis DI, Moshirfar M, Vitale AT. Bilateral acute iris transillumination following systemic moxifloxacin for respiratory illness: report of two cases and review of the literature. Ocul Immunol Inflamm 2012;20(4):266-72
   PubMed Web of Science ®Google Scholar
• Forooghian F, Maberley D, Albiani DA, et al. Uveitis risk following oral fluoroquinolone therapy: a nested case-control Study. Ocul Immunol Inflamm 2013;21(5):390-3
   PubMed Web of Science ®Google Scholar
• Skolik S, Willermain F, Caspers LE. Rifabutin-associated panuveitis with retinal vasculitis in pulmonary tuberculosis. Ocul Immunol Inflamm 2005;13(6):483-5
   PubMed Web of Science ®Google Scholar
• Frank MO, Graham MB, Wispelway B. Rifabutin and uveitis. N Engl J Med 1994;330(12):868
   PubMed Web of Science ®Google Scholar
• Smith WM, Reddy MG, Hutcheson KA, et al. Rifabutin-associated hypopyon uveitis and retinal vasculitis with a history of acute myeloid leukemia. J Ophthalmic Inflamm Infect 2012;2(3):149-52
   Google Scholar
• Bhagat N, Read RW, Rao NA, et al. Rifabutin-associated hypopyon uveitis in human immunodeficiency virus-negative immunocompetent individuals. Ophthalmology 2001;108(4):750-2
   PubMed Web of Science ®Google Scholar
• Vaudaux JD, Guex-Crosier Y. Rifabutin-induced cystoid macular oedema. J Antimicrob Chemother 2002;49(2):421-2
   PubMed Web of Science ®Google Scholar
• Chaknis MJ, Brooks SE, Mitchell KT, Marcus DM. Inflammatory opacities of the vitreous in rifabutin-associated uveitis. Am J Ophthalmol 1996;122(4):580-2
   PubMed Web of Science ®Google Scholar
• Shafran SD, Singer J, Zarowny DP, et al. Determinants of rifabutin-associated uveitis in patients treated with rifabutin, clarithromycin, and ethambutol for Mycobacterium avium complex bacteremia: a multivariate analysis. Canadian HIV Trials Network Protocol 010 Study Group. J Infect Dis 1998;177(1):252-5
   PubMed Web of Science ®Google Scholar
• Havlir D, Torriani F, Dubé M. Uveitis associated with rifabutin prophylaxis. Ann Intern Med 1194;121(7):510-12
   Google Scholar
• Narang PK, Trapnell CB, Schoenfelder JR, et al. Fluconazole and enhanced effect of rifabutin prophylaxis. N Engl J Med 1994;330(18):1316-17
   PubMed Web of Science ®Google Scholar
• Trapnell CB, Narang PK, Li R, Lavelle JP. Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients. Ann Intern Med 1996;124(6):573-6
   PubMed Web of Science ®Google Scholar
• Cato A, Cavanaugh J, Shi H, et al. The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Clin Pharmacol Ther 1998;63(4):414-21
   PubMed Web of Science ®Google Scholar
• Northrop CV, Shepherd SM, Abbuhl S. Sulfonamide-induced iritis. Am J Emerg Med 1996;14(6):577-9
   PubMed Web of Science ®Google Scholar
• Tilden ME, Rosenbaum JT, Fraunfelder FT. Systemic sulfonamides as a cause of bilateral, anterior uveitis. Arch Ophthalmol 1991;109(1):67-9
   PubMed Web of Science ®Google Scholar
• Kristinsson JK, Hannesson OB, Sveinsson O, Thorleifsson H. Bilateral anterior uveitis and retinal haemorrhages after administration of trimethoprim. Acta Ophthalmol Scand 1997;75(3):314-15
   PubMedGoogle Scholar
• Pathak S, Power B. Bilateral acute anterior uveitis as a side effect of trimethoprim. Eye (Lond) 2007;21(2):252-3
   PubMed Web of Science ®Google Scholar
• Arola O, Peltonen R, Rossi T. Arthritis, uveitis, and Stevens-Johnson syndrome induced by trimethoprim. Lancet 1998;351(9109):1102
   PubMed Web of Science ®Google Scholar
• Power WJ, Ghoraishi M, Merayo-Lloves J, et al. Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum. Ophthalmology 1995;102(11):1669-76
   PubMed Web of Science ®Google Scholar
• Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007;56(10):3248-52
   PubMed Web of Science ®Google Scholar
• Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 2014;121(3):785-96. e3
   PubMed Web of Science ®Google Scholar
• Cordero-Coma M, Yilmaz T, Onal S. Systematic review of anti-tumor necrosis factor-alpha therapy for treatment of immune-mediated uveitis. Ocul Immunol Inflamm 2013;21(1):19-27
   PubMed Web of Science ®Google Scholar
• Cunningham ET, Zierhut M. TNF inhibitors for uveitis: balancing efficacy and safety. Ocul Immunol Inflamm 2010;18(6):421-3
   PubMed Web of Science ®Google Scholar
• Suhler EB, Smith JR, Giles TR, et al. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol 2009;127(6):819-22
   PubMed Web of Science ®Google Scholar
• Taban M, Dupps WJ, Mandell B, Perez VL. Etanercept (enbrel)-associated inflammatory eye disease: case report and review of the literature. Ocul Immunol Inflamm 2006;14(3):145-50
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Perez-Alvarez R, Diaz-Lagares C, et al. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev 2010;9(3):188-93
   PubMed Web of Science ®Google Scholar
• Wendling D, Paccou J, Berthelot J-M, et al. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum 2011;41(3):503-10
   PubMed Web of Science ®Google Scholar
• Kakkassery V, Mergler S, Pleyer U. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment. Curr Eye Res 2010;35(8):751-6
   PubMed Web of Science ®Google Scholar
• Gaujoux-Viala C, Giampietro C, Gaujoux T, et al. Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease. J Rheumatol 2012;39(2):233-9
   PubMed Web of Science ®Google Scholar
• Smith JR, Levinson RD, Holland GN, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 2001;45(3):252-7
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zerón P, Soto M-J, et al. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 2008;22(5):847-61
   PubMed Web of Science ®Google Scholar
• Cunningham ET, Pasadhika S, Suhler EB, Zierhut M. Drug-induced inflammation in patients on TNFα inhibitors. Ocul Immunol Inflamm 2012;20(1):2-5
   PubMed Web of Science ®Google Scholar
• Zou J, Rudwaleit M, Brandt J, et al. Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept. Ann Rheum Dis 2003;62(6):561-4
   PubMed Web of Science ®Google Scholar
• Zou J, Rudwaleit M, Brandt J, et al. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. Arthritis Rheum 2003;48(3):780-90
   PubMed Web of Science ®Google Scholar
• Sieper J, Van Den Brande J. Diverse effects of infliximab and etanercept on T lymphocytes. Semin Arthritis Rheum 2005;34(5 Suppl1):23-7
   PubMed Web of Science ®Google Scholar
• Lügering A, Schmidt M, Lügering N, et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn’s disease by using a caspase-dependent pathway. Gastroenterology 2001;121(5):1145-57
   PubMed Web of Science ®Google Scholar
• Daïen CI, Monnier A, Claudepierre P, et al. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford) 2009;48(8):883-6
   PubMed Web of Science ®Google Scholar
• Seve P, Varron L, Broussolle C, et al. Sarcoid-related uveitis occurring during adalimumab therapy. Ocul Immunol Inflamm 2012;20(1):59-60
   PubMed Web of Science ®Google Scholar
• Ishiguro T, Takayanagi N, Kurashima K, et al. Development of sarcoidosis during etanercept therapy. Intern Med Tokyo Jpn 2008;47(11):1021-5
   Google Scholar
• Hashkes PJ, Shajrawi I. Sarcoid-related uveitis occurring during etanercept therapy. Clin Exp Rheumatol 2003;21(5):645-6
   PubMed Web of Science ®Google Scholar
• Taylor HR, Murphy RP, Newland HS, et al. Treatment of onchocerciasis. The ocular effects of ivermectin and diethylcarbamazine. Arch Ophthalmol 1986;104(6):863-70
   PubMed Web of Science ®Google Scholar
• Lariviere M, Vingtain P, Aziz M, et al. Double-blind study of ivermectin and diethylcarbamazine in African onchocerciasis patients with ocular involvement. Lancet 1985;2(8448):174-7
   PubMed Web of Science ®Google Scholar
• Greene BM, Taylor HR, Cupp EW, et al. Comparison of ivermectin and diethylcarbamazine in the treatment of onchocerciasis. N Engl J Med 1985;313(3):133-8
   PubMed Web of Science ®Google Scholar
• Anderson J, Fuglsang H, de C Marshall TF. Effects of diethylcarbamazine on ocular onchocerciasis. Tropenmed Parasitol 1976;27(3):263-78
   PubMedGoogle Scholar
• Anderson J, Fuglsang H. Further studies on the treatment of ocular onchocerciasis with diethylcarbamazine and suramin. Br J Ophthalmol 1978;62(7):450-7
   PubMed Web of Science ®Google Scholar
• Taylor HR, Greene BM. Ocular changes with oral and transepidermal diethylcarbamazine therapy of onchocerciasis. Br J Ophthalmol 1981;65(7):494-502
   PubMed Web of Science ®Google Scholar
• Jones BR, Anderson J, Fuglsang H. Effects of various concentrations of diethylcarbamazine citrate applied as eye drops in ocular onchocerciasis, and the possibilities of improved therapy from continuous non-pulsed delivery. Br J Ophthalmol 1978;62(7):428-39
   PubMed Web of Science ®Google Scholar
• Bird AC, el-Sheikh H, Anderson J, Fuglsang H. Changes in visual function and in the posterior segment of the eye during treatment of onchocerciasis with diethylcarbamazine citrate. Br J Ophthalmol 1980;64(3):191-200
   PubMed Web of Science ®Google Scholar
• Anderson J, Fuglsang H. Topical diethylcarbamazine in ocular onchocerciasis. Trans R Soc Trop Med Hyg 1973;67(5):710-17
   PubMed Web of Science ®Google Scholar
• Kirsch LS, Arevalo JF, De Clercq E, et al. Phase I/II study of intravitreal cidofovir for the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol 1995;119(4):466-76
   PubMed Web of Science ®Google Scholar
• Rahhal FM, Arevalo JF, Munguia D, et al. Intravitreal cidofovir for the maintenance treatment of cytomegalovirus retinitis. Ophthalmology 1996;103(7):1078-83
   PubMed Web of Science ®Google Scholar
• Chavez-de la Paz E, Arevalo JF, Kirsch LS, et al. Anterior nongranulomatous uveitis after intravitreal HPMPC (cidofovir) for the treatment of cytomegalovirus retinitis. Analysis and prevention. Ophthalmology 1997;104(3):539-44
   PubMed Web of Science ®Google Scholar
• Accorinti M, Ciapparoni V, Pirraglia MP, Pivetti-Pezzi P. Treatment of severe ocular hypotony in AIDS patients with cytomegalovirus retinitis and cidofovir-associated uveitis. Ocul Immunol Inflamm 2001;9(3):211-17
   PubMed Web of Science ®Google Scholar
• Taskintuna I, Banker AS, Rao NA, et al. An animal model for cidofovir (HPMPC) toxicity: intraocular pressure and histopathologic effects. Exp Eye Res 1997;64(5):795-806
   PubMed Web of Science ®Google Scholar
• Banker AS, Arevalo JF, Munguia D, et al. Intraocular pressure and aqueous humor dynamics in patients with AIDS treated with intravitreal cidofovir (HPMPC) for cytomegalovirus retinitis. Am J Ophthalmol 1997;124(2):168-80
   PubMed Web of Science ®Google Scholar
• Soltau JB. Treatment of severe ocular hypotony in AIDS patients with cytomegalovirus retinitis and cidofovir-associated uveitis. Ocul Immunol Inflamm 2001;9(3):137-9
   PubMed Web of Science ®Google Scholar
• Lin AP, Holland GN, Engstrom RE. Vitrectomy and silicone oil tamponade for cidofovir-associated hypotony with ciliary body detachment. Retina 1999;19(1):75-6
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1419-31
   PubMed Web of Science ®Google Scholar
• FDA News Release. FDA approves new drug treatment for age-related macular degeneration. FDA Press Announcements, Silver Spring, MD; 2004. Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/2004/ucm108385.htm [Last updated 2 April 2013]
   Google Scholar
• FDA News Release. FDA approves new biologic treatment for wet age-related macular degeneration. FDA Press Announcements, Silver Spring, MD; 2006. Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/2006/ucm108685.htm [Last updated 8 April 2013]
   Google Scholar
• FDA News Release. FDA approves Eylea for eye disorder in older people. FDA Press Announcements. Silver Spring, MD; 2011. Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm280601.htm [Last updated 11 March 2014]
   Google Scholar
• Kaiser RS, Gupta OP, Regillo CD, et al. Ranibizumab for eyes previously treated with pegaptanib or bevacizumab without clinical response. Ophthalmic Surg Lasers Imaging 2012;43(1):13-19
   PubMed Web of Science ®Google Scholar
• Day S, Acquah K, Mruthyunjaya P, et al. Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration. Am J Ophthalmol 2011;152(2):266-72
   PubMed Web of Science ®Google Scholar
• Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116(1):57-65
   PubMed Web of Science ®Google Scholar
• Hahn P, Kim JE, Stinnett S, et al. Aflibercept-related sterile inflammation. Ophthalmology 2013;120(5):1100-1
   PubMed Web of Science ®Google Scholar
• CATT Research Group. Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364(20):1897-908
   PubMed Web of Science ®Google Scholar
• IVAN Study Investigators. Chakravarthy U, Harding SP, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012;119(7):1399-411
   PubMed Web of Science ®Google Scholar
• O’Connor GR. Granulomatous uveitis and metipranolol. Br J Ophthalmol 1993;77(8):536-8
   PubMed Web of Science ®Google Scholar
• van Beek LM, de Keizer RJ, Polak BC, et al. Incidence of ocular side effects of topical beta blockers in the Netherlands. Br J Ophthalmol 2000;84(8):856-9
   PubMed Web of Science ®Google Scholar
• Fechtner RD, Khouri AS, Zimmerman TJ, et al. Anterior uveitis associated with latanoprost. Am J Ophthalmol 1998;126(1):37-41
   PubMed Web of Science ®Google Scholar
• Smith SL, Pruitt CA, Sine CS, et al. Latanoprost 0.005% and anterior segment uveitis. Acta Ophthalmol Scand 1999;77(6):668-72
   PubMedGoogle Scholar
• Ornek K, Onaran Z, Turgut Y. Anterior uveitis associated with fixed-combination latanoprost and timolol. Can J Ophthalmol 2008;43(6):727-8
   PubMed Web of Science ®Google Scholar
• Kiuchi Y, Okada K, Ito N, et al. Effect of a single drop of latanoprost on intraocular pressure and blood-aqueous barrier permeability in patients with uveitis. Kobe J Med Sci 2002;48(5-6):153-9
   PubMedGoogle Scholar
• Markomichelakis NN, Kostakou A, Halkiadakis I, et al. Efficacy and safety of latanoprost in eyes with uveitic glaucoma. Graefes Arch Clin Exp Ophthalmol 2009;247(6):775-80
   PubMed Web of Science ®Google Scholar
• Byles DB, Frith P, Salmon JF. Anterior uveitis as a side effect of topical brimonidine. Am J Ophthalmol 2000;130(3):287-91
   PubMed Web of Science ®Google Scholar
• Cates CA, Jeffrey MN. Granulomatous anterior uveitis associated with 0.2% topical brimonidine. Eye (Lond) 2003;17(5):670-1
   PubMed Web of Science ®Google Scholar
• Carrasco MA, Schlaen BA, Zárate JO. Brimonidine-timolol fixed combination induced granulomatous inflammation of the eye. Int Ophthalmol 2013;33(5):557-60
   PubMedGoogle Scholar
• Casado A, Cabarga C, de la Fuente MA, Muñoz-Negrete FJ. Suspected granulomatous anterior uveitis associated with brimonidine tartrate 0.2% and timolol maleate 0.5% ophthalmic solution. Graefes Arch Clin Exp Ophthalmol 2013;251(11):2659-60
   PubMed Web of Science ®Google Scholar
• Schuman JS, Horwitz B, Choplin NT, et al. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Arch Ophthalmol 1997;115(7):847-52
   PubMed Web of Science ®Google Scholar
• Kass MA, Gieser DK, Hodapp E, et al. Corticosteroid-induced iridocyclitis in a family. Am J Ophthalmol 1982;93(3):368-9
   PubMed Web of Science ®Google Scholar
• Shin DH, Kass MA, Kolker AE, et al. Positive FTA-ABS tests in subjects with corticosteroid-induced uveitis. Am J Ophthalmol 1976;82(2):259-60
   PubMed Web of Science ®Google Scholar
• Krupin T, LeBlanc RP, Becker B, et al. Uveitis in association with topically administered corticosteroid. Am J Ophthalmol 1970;70(6):883-5
   PubMed Web of Science ®Google Scholar
• Jonisch J, Lai JC, Deramo VA, et al. Increased incidence of sterile endophthalmitis following intravitreal preserved triamcinolone acetonide. Br J Ophthalmol 2008;92(8):1051-4
   PubMed Web of Science ®Google Scholar
• Wang L-C, Yang C-M. Sterile endophthalmitis following intravitreal injection of triamcinolone acetonide. Ocul Immunol Inflamm 2005;13(4):295-300
   PubMed Web of Science ®Google Scholar
• Ozkiriş A, Erkiliç K. Complications of intravitreal injection of triamcinolone acetonide. Can J Ophthalmol 2005;40(1):63-8
   PubMed Web of Science ®Google Scholar
• Moshfeghi DM, Kaiser PK, Bakri SJ, et al. Presumed sterile endophthalmitis following intravitreal triamcinolone acetonide injection. Ophthalmic Surg Lasers Imaging 2005;36(1):24-9
   PubMed Web of Science ®Google Scholar
• Otsuka H, Kawano H, Sonoda S, et al. Particle-induced endophthalmitis: possible mechanisms of sterile endophthalmitis after intravitreal triamcinolone. Invest Ophthalmol Vis Sci 2013;54(3):1758-66
   PubMed Web of Science ®Google Scholar
• Taban M, Singh RP, Chung JY-H, et al. Sterile endophthalmitis after intravitreal triamcinolone: a possible association with uveitis. Am J Ophthalmol 2007;144(1):50-4
   PubMed Web of Science ®Google Scholar
• Stepien KE, Eaton AM, Jaffe GJ, et al. Increased incidence of sterile endophthalmitis after intravitreal triamcinolone acetonide in spring 2006. Retina 2009;29(2):207-13
   PubMed Web of Science ®Google Scholar
• Yoon SJ, Rhee DY, Marx JL, et al. Anatomic and visual outcomes of noninfectious endophthalmitis after intravitreal triamcinolone. Am J Ophthalmol 2009;147(6):1031-6
   PubMed Web of Science ®Google Scholar
• Roth DB, Chieh J, Spirn MJ, et al. Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol 2003;121(9):1279-82
   PubMed Web of Science ®Google Scholar
• Nelson ML, Tennant MTS, Sivalingam A, et al. Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina 2003;23(5):686-91
   PubMed Web of Science ®Google Scholar
• Moshfeghi AA, Scott IU, Flynn HW, Puliafito CA. Pseudohypopyon after intravitreal triamcinolone acetonide injection for cystoid macular edema. Am J Ophthalmol 2004;138(3):489-92
   PubMed Web of Science ®Google Scholar
• Maia M, Farah ME, Belfort RN, et al. Effects of intravitreal triamcinolone acetonide injection with and without preservative. Br J Ophthalmol 2007;91(9):1122-4
   PubMed Web of Science ®Google Scholar
• Lubeck G, Epstein E. Complications of tattooing. Calif Med 1952;76(2):83-5
   PubMedGoogle Scholar
• Rorsman H, Brehmer-Andersson E, Dahlquist I, et al. Tattoo granuloma and uveitis. Lancet 1969;2(7610):27-8
   PubMed Web of Science ®Google Scholar
• Moschos MM, Guex-Crosier Y. Retinal vasculitis and cystoid macular edema after body tattooing: a case report. Klin Monbl Augenheilkd 2004;221(5):424-6
   PubMed Web of Science ®Google Scholar
• Saliba N, Owen ME, Beare N. Tattoo-associated uveitis. Eye (Lond) 2010;24(8):1406
   PubMed Web of Science ®Google Scholar
• Anolik R, Mandal R, Franks AG. Sarcoidal tattoo granuloma. Dermatol Online J 2010;16(11):19
   PubMedGoogle Scholar
• Fried M, Conen D, Conzelmann M, Steinemann E. Uveitis after hepatitis B vaccination. Lancet 1987;2(8559):631-2
   PubMed Web of Science ®Google Scholar
• Brézin AP, Massin-Korobelnik P, Boudin M, et al. Acute posterior multifocal placoid pigment epitheliopathy after hepatitis B vaccine. Arch Ophthalmol 1995;113(3):297-300
   PubMed Web of Science ®Google Scholar
• Bourges JL, Pisella PJ, Laurens C, Limon S. Multifocal placoid epitheliopathy and anti-hepatitis B vaccination. J Fr Ophtalmol 1998;21(9):696-700
   PubMed Web of Science ®Google Scholar
• Islam SM, El-Sheikh HF, Tabbara KF. Anterior uveitis following combined vaccination for measles, mumps and rubella (MMR): a report of two cases. Acta Ophthalmol Scand 2000;78(5):590-2
   PubMedGoogle Scholar
• Sedaghat M, Zarei-Ghanavati S, Shokoohi S, Ghasemi A. Panuveitis and dermal vasculitis following MMR vaccination. East Mediterr Health J Rev 2007;13(2):470-4
   PubMedGoogle Scholar
• Ferrini W, Aubert V, Balmer A, et al. Anterior uveitis and cataract after rubella vaccination: a case report of a 12-month-old girl. Pediatrics 2013;132(4):e1035-8
   PubMed Web of Science ®Google Scholar
• Marshall GS, Wright PF, Fenichel GM, Karzon DT. Diffuse retinopathy following measles, mumps, and rubella vaccination. Pediatrics 1985;76(6):989-91
   PubMed Web of Science ®Google Scholar
• Garip A, Diedrichs-Möhring M, Thurau SR, et al. Uveitis in a patient treated with Bacille-Calmette-Guérin: possible antigenic mimicry of mycobacterial and retinal antigens. Ophthalmology 2009;116(12):2457-62. e1-2
   PubMed Web of Science ®Google Scholar
• Ritz N, Hanekom WA, Robins-Browne R, et al. Influence of BCG vaccine strain on the immune response and protection against tuberculosis. FEMS Microbiol Rev 2008;32(5):821-41
   PubMed Web of Science ®Google Scholar
• Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006;367(9517):1173-80
   PubMed Web of Science ®Google Scholar
• Hegde V, Dean F. Bilateral panuveitis and optic neuritis following Bacillus Calmette-Guérin (BCG) vaccination. Acta Paediatr Oslo Nor 2005;94(5):635-6
   PubMed Web of Science ®Google Scholar
• Spratt A, Key T, Vivian AJ. Chronic anterior uveitis following bacille Calmette-Guérin vaccination: molecular mimicry in action? J Pediatr Ophthalmol Strabismus 2008;45(4):252-3
   PubMed Web of Science ®Google Scholar
• Jacob M, Gambrelle J, Fleury J, et al. Panuveitis following intravesical bacille Calmette-Guerin therapy]. J Fr Ophtalmol 2006;29(5):552-5
   PubMed Web of Science ®Google Scholar
• Uppal GS, Shah AN, Tossounis CM, Tappin MJ. Bilateral panuveitis following intravesical BCG immunotherapy for bladder carcinoma. Ocul Immunol Inflamm 2010;18(4):292-6
   PubMed Web of Science ®Google Scholar
• Guex-Crosier Y, Chamot L, Zografos L. Chorioretinitis induced by intravesical Bacillus Calmette-Guérin (BCG) instillations for urinary bladder carcinoma. Klin Monatsblätter Für Augenheilkd 2003;220(3):193-5
   PubMed Web of Science ®Google Scholar
• Sharan S, Thirkill CE, Grigg JR. Autoimmune retinopathy associated with intravesical BCG therapy. Br J Ophthalmol 2005;89(7):927-8
   PubMed Web of Science ®Google Scholar
• Takeuchi A, Taguchi M, Satoh Y, et al. Bilateral orbital inflammation following intravesical bacille Calmette-Guérin immunotherapy for bladder cancer. Jpn J Ophthalmol 2012;56(2):187-9
   PubMed Web of Science ®Google Scholar
• Han DP, Simons KB, Tarkanian CN, Moretti ST. Endophthalmitis from Mycobacterium bovis-bacille Calmette-Guérin after intravesicular bacille Calmette-Guérin injections for bladder carcinoma. Am J Ophthalmol 1999;128(5):648-50
   PubMed Web of Science ®Google Scholar
• Chevrel G, Zech C, Miossec P. Severe uveitis followed by reactive arthritis after bacillus Calmette-Guérin therapy. J Rheumatol 1999;26(4):1011
   PubMed Web of Science ®Google Scholar
• Pancaldi P, Van Linthoudt D, Alborino D, et al. Reiter’s syndrome after intravesical Bacillus Calmette-Guérin treatment for superficial bladder carcinoma. Br J Rheumatol 1993;32(12):1096-8
   PubMedGoogle Scholar
• Blanche P, Decrette C, Sicard D. Development of uveitis following vaccination for influenza. Clin Infect Dis 1994;19(5):979
   PubMed Web of Science ®Google Scholar
• Knopf HL. Recurrent uveitis after influenza vaccination. Ann Ophthalmol 1991;23(6):213-14
   PubMed Web of Science ®Google Scholar
• Bienfang DC, Kantrowitz FG, Noble JL, Raynor AM. Ocular abnormalities after influenza immunization. Arch Ophthalmol 1977;95(9):1649
   PubMed Web of Science ®Google Scholar
• Blumberg S, Bienfang D, Kantrowitz FG. A possible association between influenza vaccination and small-vessel vasculitis. Arch Intern Med 1980;140(6):847-8
   PubMed Web of Science ®Google Scholar
• Mendrinos E, Baglivo E. Acute posterior multifocal placoid pigment epitheliopathy following influenza vaccination. Eye (Lond) 2010;24(1):180-1
   PubMed Web of Science ®Google Scholar
• Tao Y, Chang L-B, Zhao M, Li X-X. Two cases of exudative retina detachment and uveitis following H1N1 influenza vaccination. Chin Med J (Engl) 2011;124(22):3838-40
   PubMed Web of Science ®Google Scholar
• Thurairajan G, Hope-Ross MW, Situnayake RD, Murray PI. Polyarthropathy, orbital myositis and posterior scleritis: an unusual adverse reaction to influenza vaccine. Br J Rheumatol 1997;36(1):120-3
   PubMedGoogle Scholar
• Kawasaki A, Purvin VA, Tang R. Bilateral anterior ischemic optic neuropathy following influenza vaccination. J Neuro-Ophthalmol 1998;18(1):56-9
   PubMed Web of Science ®Google Scholar
• Rothova A, de Groot JDF, Mudrikova T. Reactivation of acute retinal necrosis after flu H1N1 vaccination. Br J Ophthalmol 2011;95(2):291
   PubMed Web of Science ®Google Scholar
• Walter R, Hartmann K, Fleisch F, et al. Reactivation of herpesvirus infections after vaccinations? Lancet 1999;353(9155):810
   PubMed Web of Science ®Google Scholar
• Naseri A, Good WV, Cunningham ET. Herpes zoster virus sclerokeratitis and anterior uveitis in a child following varicella vaccination. Am J Ophthalmol 2003;135(3):415-17
   PubMed Web of Science ®Google Scholar
• Esmaeli-Gutstein B, Winkelman JZ. Uveitis associated with varicella virus vaccine. Am J Ophthalmol 1999;127(6):733-4
   PubMed Web of Science ®Google Scholar
• Lin P, Yoon MK, Chiu CS. Herpes zoster keratouveitis and inflammatory ocular hypertension 8 years after varicella vaccination. Ocul Immunol Inflamm 2009;17(1):33-5
   PubMed Web of Science ®Google Scholar
• Chouliaras G, Spoulou V, Quinlivan M, et al. Vaccine-associated herpes zoster ophthalmicus correction of opthalmicus] and encephalitis in an immunocompetent child. Pediatrics 2010;125(4):e969-72
   PubMed Web of Science ®Google Scholar
• Hwang CW, Steigleman WA, Saucedo-Sanchez E, Tuli SS. Reactivation of herpes zoster keratitis in an adult after varicella zoster vaccination. Cornea 2013;32(4):508-9
   PubMed Web of Science ®Google Scholar
• Sanford M, Keating GM. Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Drugs Aging 2010;27(2):159-76
   PubMed Web of Science ®Google Scholar
• Murray AV, Reisinger KS, Kerzner B, et al. Safety and tolerability of zoster vaccine in adults ≥60 years old. Hum Vaccin 2011;7(11):1130-6
   PubMed Web of Science ®Google Scholar
• Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK. Acute retinal necrosis after herpes zoster vaccination. Arch Ophthalmol 2011;129(11):1495-7
   PubMed Web of Science ®Google Scholar
• Khalifa YM, Jacoby RM, Margolis TP. Exacerbation of zoster interstitial keratitis after zoster vaccination in an adult. Arch Ophthalmol 2010;128(8):1079-80
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB. Investigation of anterior uveitis. Can J Ophthalmol 2008;43(6):630-3
   PubMed Web of Science ®Google Scholar
• Noble J, Hollands H, Forooghian F, et al. Evaluating the cost-effectiveness of anterior uveitis investigation by Canadian ophthalmologists. Can J Ophthalmol 2008;43(6):652-7
   PubMed Web of Science ®Google Scholar